research use only
Cat.No.S3841
| Related Targets | PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other Immunology & Inflammation related Inhibitors | Cl-amidine Bestatin (Ubenimex) Bindarit (AF 2838) Tranilast Tempol Sinomenine GI254023X (GI4023) ATP Geniposidic acid CORM-3 |
|
In vitro |
DMSO
: 74 mg/mL
(198.72 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 372.37 | Formula | C17H24O9 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 118-34-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | syringin, Syringoside, Lilacin | Smiles | COC1=CC(=CC(=C1OC2C(C(C(C(O2)CO)O)O)O)OC)C=CCO | ||
| In vitro |
Syringin shows low cytotoxicity on the U937 and PBMC cells with IC50 of >100 and 91.14 mg/mL, respectively.
|
|---|---|
| In vivo |
Syringin has a potent protection against LPS/D-GalN-induced fulminant hepatic failure (FHF), as indicated by the decreased high lethality, alleviates hepatic pathological injury, inhibits hepatocytes apoptosis and reduces hepatic inflammatory responses. Such protective effects are probably carried out through suppression of TNF-α production, which is mediated by NF-kB. Syringin also protects against LPS-induced acute lung injury (ALI) by activating Nrf2 and inhibiting NF-κB signaling pathway. Syringin improves glucose tolerance without increased weight gain in high-fat diet-induced obese mice. It augmentes insulin-stimulated Akt phosphorylation in skeletal muscle, epididymal adipose tissue (EAT), and the liver, showing an insulin-sensitizing activity. Syringin-treated mice also show markedly elevated adiponectin production in EAT and suppresses expression of pro-inflammatory cytokines in peripheral tissues, indicating a significant reduction in low-grade chronic inflammation. Additionally, syringin enhances AMP-activated protein kinase activity and decreases the expression of lipogenic genes in skeletal muscle, which is associated with reduced endoplasmic reticulum (ER) stress.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.